Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

FDA Grants Fast Track Designation to Ultimovacs ASA’s UV1

Feb 5, 2024

On 5 February 2024, Ultimovacs announced that the FDA has granted a fast-track designation to its therapeutic cancer vaccine UV1 in combination with nivolumab and ipilimumabThis was supported by the results of a phase II clinical trial for the treatment of patients with unresectable malignant pleural mesothelioma.